An extensive phenotypic characterization of the hTNFα transgenic mice-0

<p><b>Copyright information:</b></p><p>Taken from "An extensive phenotypic characterization of the hTNFα transgenic mice"</p><p>http://www.biomedcentral.com/1472-6793/7/13</p><p>BMC Physiology 2007;7():13-13.</p><p>Published online 10 Dec 2007</p><p>PMCID:PMC2222242.</p><p></p>pendently increased endogenous TNFα in WT and TG mice similarly. WT (open bars) and TG mice (closed bars) were injected with the indicated doses of LPS (μg/mouse) as shown on the X-axis. (A) Human and (B) mouse TNFα levels were measured using ELISA assays. Data are presented as means ± SEM, n = 5 for each genotype and dose combination. ND – non-detectable

An extensive phenotypic characterization of the hTNFα transgenic mice-2

<p><b>Copyright information:</b></p><p>Taken from "An extensive phenotypic characterization of the hTNFα transgenic mice"</p><p>http://www.biomedcentral.com/1472-6793/7/13</p><p>BMC Physiology 2007;7():13-13.</p><p>Published online 10 Dec 2007</p><p>PMCID:PMC2222242.</p><p></p>pendently increased endogenous TNFα in WT and TG mice similarly. WT (open bars) and TG mice (closed bars) were injected with the indicated doses of LPS (μg/mouse) as shown on the X-axis. (A) Human and (B) mouse TNFα levels were measured using ELISA assays. Data are presented as means ± SEM, n = 5 for each genotype and dose combination. ND – non-detectable

Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation

A new subseries of ROMK inhibitors exemplified by <b>28</b> has been developed from the initial screening hit <b>1</b>. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of <b>28</b> as a new mechanism diuretic. Robust pharmacodynamic effects in both SD rats and dogs have been demonstrated